Literature DB >> 18687789

A pseudo-full mutation identified in fragile X assay reveals a novel base change abolishing an EcoRI restriction site.

Shujian Liang1, Harold N Bass, Hanlin Gao, Caroline Astbury, Mehdi R Jamehdor, Yong Qu.   

Abstract

Diagnostic testing for the fragile X syndrome is designed to detect the most common mutation, a CGG expansion in the 5'-untranslated region of the fragile X mental retardation (FMRI) gene. PCR can determine the number of CGG repeats less than 100, whereas Southern analysis can detect large premutations, full mutations, and their methylation status. Bands larger than 5.8 kb observed via Southern analysis are usually considered a methylated full mutation, causing fragile X syndrome in males and varied clinical presentations in females. We observed a 10.9-kb band on a Southern blot assay from an autistic girl with language delay. Further investigation identified a novel G-to-A transition at an EcoRI cleavage site, upstream of the CGG repeat region of the FMRI gene. This base change abolished the EcoRI restriction site, resulting in a 10.9-kb pseudo-full mutation. This G-to-A base change has not been previously reported and was not identified in a subsequent analysis of 105 male and 30 female patient samples. The clear 10.9-kb band detected on a Southern blot assay for fragile X syndrome mimics a large, methylated full mutation, which could result in a misdiagnosis without the benefit of family studies and further testing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18687789      PMCID: PMC2518742          DOI: 10.2353/jmoldx.2008.080059

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  6 in total

1.  Novel polymorphism in the FMR1 gene resulting in a "pseudodeletion" of FMR1 in a commonly used fragile X assay.

Authors:  T M Daly; A Rafii; R A Martin; B A Zehnbauer
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

2.  Five years of molecular diagnosis of Fragile X syndrome (1997-2001): a collaborative study reporting 95% of the activity in France.

Authors:  Valérie Biancalana; Chérif Beldjord; Agnès Taillandier; Sylvie Szpiro-Tapia; Véronica Cusin; Fabienne Gerson; Christophe Philippe; Jean-Louis Mandel
Journal:  Am J Med Genet A       Date:  2004-09-01       Impact factor: 2.802

3.  Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox.

Authors:  Y H Fu; D P Kuhl; A Pizzuti; M Pieretti; J S Sutcliffe; S Richards; A J Verkerk; J J Holden; R G Fenwick; S T Warren
Journal:  Cell       Date:  1991-12-20       Impact factor: 41.582

4.  Duplication of the 15q11-13 region in a patient with autism, epilepsy and ataxia.

Authors:  S Bundey; C Hardy; S Vickers; M W Kilpatrick; J A Corbett
Journal:  Dev Med Child Neurol       Date:  1994-08       Impact factor: 5.449

Review 5.  FMR1 and the fragile X syndrome: human genome epidemiology review.

Authors:  D C Crawford; J M Acuña; S L Sherman
Journal:  Genet Med       Date:  2001 Sep-Oct       Impact factor: 8.822

6.  Fragile X syndrome: diagnostic and carrier testing.

Authors:  Stephanie Sherman; Beth A Pletcher; Deborah A Driscoll
Journal:  Genet Med       Date:  2005-10       Impact factor: 8.822

  6 in total
  3 in total

1.  Clinical utility gene card for: fragile X mental retardation syndrome, fragile X-associated tremor/ataxia syndrome and fragile X-associated primary ovarian insufficiency.

Authors:  Sebastien Jacquemont; Stefanie Birnbaum; Silke Redler; Peter Steinbach; Valérie Biancalana
Journal:  Eur J Hum Genet       Date:  2011-05-04       Impact factor: 4.246

Review 2.  Recent advances in assays for the fragile X-related disorders.

Authors:  Bruce E Hayward; Daman Kumari; Karen Usdin
Journal:  Hum Genet       Date:  2017-09-02       Impact factor: 4.132

3.  EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders.

Authors:  Valérie Biancalana; Dieter Glaeser; Shirley McQuaid; Peter Steinbach
Journal:  Eur J Hum Genet       Date:  2014-09-17       Impact factor: 4.246

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.